Treace to Present at the Sidoti Small Cap Conference

Treace (Nasdaq: TMCI) will present at the Sidoti Small Cap Conference on Thursday, June 18, 2026, starting around 1:45 pm ET.

Rhea-AI Summary

Treace (Nasdaq: TMCI) will present at the Sidoti Small Cap Conference on Thursday, June 18, 2026, starting around 1:45 pm ET.

A live webcast and replay will be available on Treace’s investor relations website, where the company also posts information that may be important to investors.

Argus Jun 12 session

+3.84% close to close Open Argus

Details

News Market Reaction – TMCI

In the Jun 12 session, TMCI gained 3.84%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Treace’s upcoming presentation at the Sidoti Small Cap Conference on Ju...

Analysis

This announcement highlights Treace’s upcoming presentation at the Sidoti Small Cap Conference on June 18, 2026 at 1:45 pm ET, signaling continued engagement with investors. In the months leading up to this, the company reported Q1 2026 revenue of $47.2M with a net loss of $18.0M and introduced new products and positive clinical data. Investors may watch future earnings, commercialization milestones, and additional clinical updates for further clarity on execution.

Key Figures

Conference date: June 18, 2026 Presentation time: 1:45 pm ET

Conference date

June 18, 2026

Sidoti Small Cap Conference presentation date

Presentation time

1:45 pm ET

Start time of Sidoti conference presentation

Historical Context

5 past events · Latest: May 08

5 events

1. May 08

   Q1 2026 earnings

   24h Move

   +4.7%

   Reported revenue decline and net loss but reaffirmed 2026 guidance.

2. Apr 24

   Earnings call date

   24h Move

   +8.8%

   Announced date and access details for Q1 2026 results call.

3. Apr 07

   Product launch news

   24h Move

   -6.9%

   Announced first surgical cases with new SuperBite screw system, expanding market.

4. Feb 27

   FY 2025 earnings

   24h Move

   -11.4%

   Reported modest revenue growth with improved adjusted EBITDA but ongoing losses.

5. Feb 24

   Clinical data update

   24h Move

   -2.0%

   Presented favorable ALIGN3D recurrence and union data plus new device previews.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

midfoot deformities, nasdaqgs

2 terms

midfoot deformities medical

"surgical treatment of bunions and related midfoot deformities, today announced it"

Midfoot deformities are structural problems in the middle section of the foot where the bones and soft tissues that form the foot’s arch become misaligned or weakened, like the bridge of a foot sagging or twisting. They matter to investors because they can reduce mobility and quality of life, driving demand for medical devices, surgical procedures, therapies, and reimbursement decisions that affect healthcare companies’ revenues and regulatory approvals.

nasdaqgs financial

"Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental"

NASDAQGS indicates a company’s shares trade on the NASDAQ Global Select Market, one of the exchange’s top tiers with stricter listing rules. Like a quality label or neighborhood sign, it tells investors the company meets higher standards for size, reporting and governance, which can mean better transparency, easier buying and selling, and greater appeal to institutional investors — all factors that affect a stock’s risk and liquidity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will present at the Sidoti Small Cap Conference, Thursday, June 18, 2026, beginning at approximately 1:45 pm ET.

A live webcast and replay of the presentation will be available on the Company’s investors relations website at https://investors.treace.com/.

Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty^®3D Bunion Correction^® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty^® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty^® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System, and the SpeedMTP^® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate^® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide^® patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Treace (TMCI) present at the Sidoti Small Cap Conference in 2026?

Treace is scheduled to present on Thursday, June 18, 2026, beginning at approximately 1:45 pm ET. According to Treace, this appearance is part of the Sidoti Small Cap Conference.

How can investors watch Treace’s (TMCI) Sidoti Small Cap Conference presentation?

Investors can watch a live webcast of Treace’s presentation via the company’s investor relations website. According to Treace, a replay of the presentation will also be available online.

Where is Treace’s (TMCI) investor relations website for the Sidoti conference webcast?

The webcast and replay will be hosted on Treace’s investor relations website at https://investors.treace.com/. According to Treace, this site is the primary hub for its investor-focused information and updates.

What type of company is Treace (TMCI), presenting at the Sidoti Small Cap Conference?

Treace is a medical technology company focused on surgical treatment of bunions and midfoot deformities. According to Treace, it is driving a fundamental shift in these procedures through its specialized solutions.

Where can investors find ongoing important information about Treace (TMCI)?

Investors can find important information in the Investor Relations section of www.treace.com. According to Treace, the company routinely posts updates there and encourages investors to check the site regularly.